Immunotherapy plus R-CHOP for untreated PMBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called primary mediastinal B-cell lymphoma (PMBCL) that hasn't been treated yet.
- You must be between 18 and 75 years old.
- You need to have a tumor sample available from a past or fresh biopsy.
- You should be in fairly good health (ECOG score 0-2) and have enough organ function (like heart, liver, kidneys).
- You cannot have had prior treatment with certain immunotherapy drugs (like PD-1 inhibitors) or have an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This Phase 2 trial tests a PD-1 antibody (anti–PD-1) added to standard R-CHOP chemotherapy for certain people with diffuse large B-cell lymphoma (DLBCL) who have a p53 mutation and tumor PD-L1 expression. It may help shrink lymphoma more effectively when these tumor markers are present.
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a new sequence of chemotherapy drugs for people with intermediate-to-high risk diffuse large B-cell lymphoma who did not achieve complete remission after their first two cycles of standard treatment. The goal is to see if this approach is safe and effective.
Hear when a new Primary Mediastinal Diffuse Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.